PDCD1 and plasma cell myeloma: Moreover, a randomized phase 3 trial including a checkpoint inhibitor combined with an immunomodulatory substance and dexamethasone for patients with relapsed or refractory multiple myeloma was unsuccessful, raising questions about future targeting of PD-1 and PD-L1 in myeloma [32,33].